.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Citi
US Department of Justice
Fuji
McKesson
QuintilesIMS
Colorcon
Teva
Chinese Patent Office

Generated: December 13, 2017

DrugPatentWatch Database Preview

ZYKADIA Drug Profile

« Back to Dashboard

When do Zykadia patents expire, and when can generic versions of Zykadia launch?

Zykadia is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are twelve patents protecting this drug.

This drug has three hundred and sixty-one patent family members in fifty-four countries and eighteen supplementary protection certificates in ten countries.

The generic ingredient in ZYKADIA is ceritinib. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZYKADIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,803,9392,4-pyrimidinediamine compounds and their uses► Subscribe
7,642,3512,4-Pyrimidinediamine compounds and their uses► Subscribe
7,329,6712,4-pyrimidinediamine compounds and their uses► Subscribe
7,820,8192,4-pyrimidinediamine compounds and their uses► Subscribe
9,162,9892,4-Pyrimidinediamine compounds and their uses► Subscribe
9,346,7652,4-pyrimidinediamine compounds and their uses► Subscribe
7,557,2102,4-pyrimidinediamine compounds and their uses► Subscribe
9,133,1332,4-pyridinediamine compounds and their uses► Subscribe
9,040,5502,4-pyrimidinediamine compounds and their uses► Subscribe
7,498,4352,4-pyrimidinediamine compounds and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZYKADIA

Country Document Number Estimated Expiration
Ukraine81758► Subscribe
Japan5357116► Subscribe
Israel226474► Subscribe
EcuadorSP099500► Subscribe
Portugal1471915► Subscribe
China103169708► Subscribe
Cyprus1112571► Subscribe
World Intellectual Property Organization (WIPO)2008073687► Subscribe
World Intellectual Property Organization (WIPO)2004080980► Subscribe
Mexico2013006952► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZYKADIA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
7 5020-2015Slovakia► SubscribePRODUCT NAME: CERITINIB; REGISTRATION NO/DATE: EU/1/15/999 20150508
824Luxembourg► SubscribePRODUCT NAME: CERITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20150508
C0064France► SubscribePRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/15/999 20150508
2015 00050Denmark► SubscribePRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 20150508
2015034,C2091918Lithuania► SubscribePRODUCT NAME: CERITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/999 20150506
2015 00050Denmark► SubscribePRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 20150508
0150037 00157Estonia► SubscribePRODUCT NAME: TSERITINIIB;REG NO/DATE: EU/1/15/999 08.05.2015
C0058France► SubscribePRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/999 20150508
90054-1Sweden► SubscribePRODUCT NAME: CERITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/15/999 20150508
2015000076Germany► SubscribePRODUCT NAME: CERITINIB ODER PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/999 20150506
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Fuji
Express Scripts
Queensland Health
QuintilesIMS
McKesson
Deloitte
AstraZeneca
Accenture
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot